Ophthalmology · Diagnostic ImagingRegulatory Approvalregulatorymid-term

FDA Accepts Supplement Application for IC-GREEN by RENEW PHARMS

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/5/2026, 6:05:39 AM

Assessment confidence: 41% · The main uncertainty is whether medium-relevance evidence fully captures sub-indication-specific dynamics.

Executive Thesis

The FDA's acceptance of the supplemental application for IC-GREEN is a significant regulatory milestone for RENEW PHARMS, potentially enhancing its competitive position in the ophthalmology diagnostic imaging market. This development underscores the importance of monitoring FDA timelines and subsequent approval announcements to inform strategic planning. Regulatory context from FDA (FDA AP — IC-GREEN (SUPPL)) supports the near-term read. Assessment grounded in 2 ranked evidence items (0 high-relevance).

Strategic Assessment

Strategic focus on expanding the portfolio of imaging agents could strengthen RENEW PHARMS' market presence. The strongest clinical anchor is Development of Magnetic Resonance Spectroscopic Imaging Techniques for Imaging Metabolites in Human Brain and Muscle (ClinicalTrials.gov), weak alignment to signal sub-indication and entities. In ophthalmology, 1 regulatory and 0 competitive items passed relevance filtering for RENEW PHARMS.

Competitive Pressure

The most relevant competitive pressure comes from This acceptance may enhance RENEW PHARMS' position in the diagnostic imaging market, particularly in ophthalmology..

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — IC-GREEN (SUPPL) (FDA). Entity match (renew pharms). The acceptance of the supplemental application indicates a favorable regulatory pathway, but the final approval remains contingent on the FDA's review process.

Key Risks

Elevated medium regulatory exposure for RENEW PHARMS could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Successful approval could lead to increased market share for RENEW PHARMS in the diagnostic imaging sector, impacting revenue positively through expanded product offerings.
Strategic focus on expanding the portfolio of imaging agents could strengthen RENEW PHARMS' market presence.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for FDA review and any subsequent approval announcements.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — IC-GREEN (SUPPL)
FDAmedium relevance
Entity match (renew pharms)
FDA document
View source
IND Application Reporting: IND Safety Reports
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Investigational New Drug (IND) Application
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA AP — ARGATROBAN IN 0.9% SODIUM CHLORIDE (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA AP — ROMVIMZA (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA AP — CICLOPIROX (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA AP — Xeomin (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Development of Magnetic Resonance Spectroscopic Imaging Techniques for Imaging Metabolites in Human Brain and Muscle
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Pomegranate Dietary Supplements in AUD and ALD
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Diagnostic Utility of Cardiac MRI
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Approves Supplemental Application for Cosentyx (Secukinumab)
Humanexa Signalslow relevance
Sponsor/company relevance (Novartis)
FDA Accepts Supplemental Application for TRYNGOLZA Autoinjector
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

A 3.6:1 myo-inositol to D-chiro-inositol ratio and antioxidant-based food supplement before IVF improves fertility in women with PCOS: a pilot observational retrospective cohort study.
PubMedmedium relevance
Mechanism alignment (IO )
FDA document
View source
Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

RENEW PHARMS
IC-GREEN
diagnostic imaging sector

Commercial impact

medium

Successful approval could lead to increased market share for RENEW PHARMS in the diagnostic imaging sector, impacting revenue positively through expanded product offerings.

Regulatory impact

medium

The acceptance of the supplemental application indicates a favorable regulatory pathway, but the final approval remains contingent on the FDA's review process.

What to watch

Monitor the timeline for FDA review and any subsequent approval announcements.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.